Expressão imuno-histoquímica das proteínas VEGF e HER-2 em biópsias de osteossarcoma

Becker, Ricardo Gehrke; Gália, Carlos Roberto; Morini, Sandra; Viana, Cristiano Ribeiro

doi:10.1590/s1413-78522013000400010

Cited by 14 publications

(2 citation statements)

References 16 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When comparing with the literature, we see that most of the similar studies do not even mention local recurrence as a variable. 5 , 9 , 13 , 14 , 17 , 22 In the few studies that mention local recurrence, numbers obtained were similar to the present study. Lee et al 2 and Lin et al 16 reported the same 20% of local recurrence of the present series.…”

Section: Discussionsupporting

confidence: 89%

Correlation between the expression of vegf and survival in osteosarcoma

et al. 2014

View full text Add to dashboard Cite

Objective: To present a series of 50 consecutive patients with non-metastatic extremity osteosarcoma, and attempt to correlate expression of the vascular endothelial growth factor (VEGF) protein in biopsy tissue to their prognosis regarding overall survival, disease-free survival and local recurrence. Methods: Fifty cases of non-metastatic osteosarcoma of the extremities treated between 1986 and 2006 at Instituto de Ortopedia e Traumatologia da Universidade de São Paulo, São Paulo, Brasil, were evaluated regarding expression of the VEGF protein. There were 19 females and 31 males. The mean age was 16 years old (range 5-28 years old) and the mean follow-up was 60.6 months (range 25-167 months). The variables studied were age, gender, anatomic location, type of surgery, surgical margins, tumor size, post chemotherapy necrosis, local recurrence, pulmonary metastasis and death. Results: Thirty-six patients showed VEGF expression on 30% or less cells (low), and the remaining 14 cases had VEGF expression above 30% (high). Among the 36 patients with low VEGF expression, nine developed pulmonary metastasis and four died (11.1%). Among the 14 patients with high VEGF expression, six developed pulmonary metastasis and three died (21.4%). Conclusion: There was no statistically significant correlation between the expression of VEGF and any of the variables studied. Level of Evidence IV, Therapeutic Study.

show abstract

Section: Discussionsupporting

confidence: 89%

Correlation between the expression of vegf and survival in osteosarcoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…HER-2 overexpression was documented in 42.2% of patients. Among these studies, HER-2 positivity was evaluated as 12.5% to 13.4% in 2 [ 20 – 21 ] studies (12.5%), as 30.8% to 32.1% in 2 [ 6 , 22 ] studies (12.5%), as 42.3% to 49.3% in 7 [ 7 , 16 – 18 , 23 – 24 , 27 ] studies (43.8%), as 55.3% in 1 [ 15 ] study (6.3%) and as 61.5% to 65% in 4 [ 14 , 19 , 25 – 26 ] studies (25%). Only 1 [ 20 ] used a prospective design; the others used a retrospective cohort design.…”

Section: Resultsmentioning

confidence: 99%

HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma

Liu

Wang

et al. 2016

Medicine

View full text Add to dashboard Cite

Numerous original clinical studies have attempted to investigate the prognostic value of HER-2 overexpression in osteosarcoma, but the results of these studies are not consistent. This meta-analysis and systematic review was performed to further assess the correlation between HER-2 expression and prognosis in patients with osteosarcoma. A detailed search of relevant publications was conducted using 7 electronic databases: PubMed, Embase, the Cochrane library, the Wanfang database, the China National Knowledge Internet (CNKI) database, the Chinese VIP database, and the Chinese Biological Medical (CBM) Database for publications through August 1, 2015, using the following keywords (HER-2 OR ErbB-2 OR C-erbB-2 OR neu) AND (osteosarcoma OR osteogenic tumor). The bibliographies of potentially relevant articles and identified articles were then searched by hand. Eligible studies were those that enrolled participants with osteosarcoma and provided survival outcome in HER-2 positive and negative groups. The hazard ratio (HR) and 95% confidence interval (CI) for each individual study was calculated and pooled to obtain integrated estimates, using random effects modeling. Sixteen studies involving 934 participants with osteosarcoma met our inclusion criteria. HER-2 overexpression was documented in 42.2% of patients with osteosarcoma. Compared with patients without HER-2 overexpression, those overexpressing HER-2 had decreased overall survival (HR = 2.03, 95% CI: 1.36–3.03, P < 0.001). Statistical associations between HER-2 overexpression and unfavorable overall survival (OS) were observed for both biopsy and surgical removal specimens (HR = 2.07, 95%CI: 1.16–3.72, P = 0.014; and HR = 2.02, 95%CI: 1.10–3.71, P = 0.024). Results for disease-free survival (DFS) were similar. Overexpression of HER-2 is significantly associated with poor outcome for patients with osteosarcoma and should be assessed at diagnosis and after surgery as a prognostic factor. However, larger-scale multicenter clinical studies are needed to further support these findings.

show abstract

Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma

Han

Wang

et al. 2015

Clin Exp Med

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) has been linked with tumor invasion and metastasis. However, the role of VEGF expression in osteosarcoma remains controversial. By searching the PubMed, Embase, and Google Scholar databases, we conducted a meta-analysis to evaluate the pathological and prognostic significance of VEGF in osteosarcoma. Studies were pooled, and the odds ratio (OR) and its corresponding 95 % confidence interval (CI) were calculated. Nine relevant articles were included in this meta-analysis study. We performed pooled analysis with available data on the association between VEGF expression and age, gender, tumor stages IIB-III versus I-IIA, tumor recurrence, response to chemotherapy, and tumor metastasis. Our results revealed that VEGF expression might be closely associated with metastasis of osteosarcoma (OR 4.74, 95 % CI 2.53-8.87, P < 0.001). Furthermore, our findings also demonstrated that patients with grade IIB-III osteosarcoma showed a higher frequency of VEGF expression than those with grade I-IIA osteosarcoma (OR 5.33, 95 % CI 2.03-13.98, P = 0.001). We failed to find the association between VEGF expression and age (OR 0.82, 95 % CI 0.44-1.53, P = 0.539), gender (OR 1.33, 95 % CI 0.52-3.42, P = 0.553), tumor recurrence (OR 1.47, 95 % CI 0.56-3.86, P = 0.429), and response to chemotherapy (OR 1.26, 95 % CI 0.14-11.72, P = 0.839). In conclusion, VEGF is related to the grade and metastasis of osteosarcoma. It may play a significant role in clinical guidelines for the treatment and prognostic evaluation.

show abstract

Expressão imuno-histoquímica das proteínas VEGF e HER-2 em biópsias de osteossarcoma

Cited by 14 publications

References 16 publications

Correlation between the expression of vegf and survival in osteosarcoma

Correlation between the expression of vegf and survival in osteosarcoma

HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma

Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma

Contact Info

Product

Resources

About